WASHINGTON — Like drug industry CEOs before them, drug middlemen are headed for the congressional hot seat.

Sens. Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.), who lead the Senate Finance Committee, have invited five major pharmacy benefit managers, Cigna, CVS, Humana, OptumRx and Prime Therapeutics, to testify before Congress on April 3, the pair announced Tuesday afternoon.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Well it’s about time !!! I just hope they know the right questions to ask the PBM’s. Like about Drug rebates really being a payoff to be on formulary. How about the PBM’s stealing the Price spread between AWP and what they pay the pharmacy. Why is there no transparency in their payment system? How is it that audits of 10 states medicaid systems uncovered billions of dollars stolen by the PBM’s. Why would the PBM’s bill medicare part D patients at AWP ? This puts them in the donut hole so much faster ! Why do PBM’s have a take it or leave it contract with Independent pharmacies but no one has any idea if there is any contract with their own pharmacies.
    Is it not a conflict of interest that the PBM’s decide how much they pay independent pharmacies and how much they pay themselves . Gee this sounds so much like Anti-trust to me !!!!!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy